Quality of life rapidly improves with budesonide therapy for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group.

Abstract:

:Our aims were to assess the impact on health-related quality of life (HRQOL) of a controlled ileal release (CIR) formulation of budesonide in active Crohn's disease (CD) and further define the role of HRQOL, using the Inflammatory Bowel Disease Questionnaire (IBDQ), in assessing outcome in CD. A randomized trial was conducted in 258 patients with active ileal or ileocecal CD. Budesonide CIR 1.5 mg, 4.5 mg, 7.5 mg, or placebo was given b.i.d. for 8 weeks. IBDQ score changes were compared among groups. Correlations for IBDQ and Crohn's Disease Activity Index (CDAI) scores were calculated. Mean IBDQ scores improved significantly over placebo by 2 weeks in budesonide 15 mg (155+/-38; p = 0.006) and 9 mg groups (157+/-33; p = 0.0002). Bowel, systemic, social, and emotional subscores were also significantly better (p < 0.002) at 2 and 8 weeks in the 9 mg group. Improved HRQOL scores correlated well with decreased CDAI (-0.8 < r < -0.4). Average per item change in IBDQ at remission was 1.17 to 1.48. Prior surgery (p < 0.005) or current smoker (p < 0.05) status predicted poorer initial HRQOL but not response. Budesonide CIR 9 or 15 mg/day rapidly and significantly improved HRQOL in active CD.

journal_name

Inflamm Bowel Dis

authors

Irvine EJ,Greenberg GR,Feagan BG,Martin F,Sutherland LR,Thomson AB,Nilsson LG,Persson T

doi

10.1097/00054725-200008000-00004

keywords:

subject

Has Abstract

pub_date

2000-08-01 00:00:00

pages

181-7

issue

3

eissn

1078-0998

issn

1536-4844

journal_volume

6

pub_type

临床试验,杂志文章,随机对照试验
  • Faecalibacterium prausnitzii Produces Butyrate to Maintain Th17/Treg Balance and to Ameliorate Colorectal Colitis by Inhibiting Histone Deacetylase 1.

    abstract:BACKGROUND:Inflammatory bowel disease (IBD)-associated dysbiosis is characterized by a loss of Faecalibacterium prausnitzii, whose supernatant exerts an anti-inflammatory effect. However, the anti-inflammatory substances in F. prausnitzii supernatant and the mechanism in ameliorating colitis in IBD have not yet been fu...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izy182

    authors: Zhou L,Zhang M,Wang Y,Dorfman RG,Liu H,Yu T,Chen X,Tang D,Xu L,Yin Y,Pan Y,Zhou Q,Zhou Y,Yu C

    更新日期:2018-08-16 00:00:00

  • Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis.

    abstract:BACKGROUND:High doses of mesalazine usually result in an inconvenient dosage schedule and reduced compliance. The goal of this trial was to compare the effects of mesalazine 4 g daily given as prolonged-release granules in packets of 1 g with that of prolonged-release tablets of 0.5 g. METHODS:Two hundred twenty-seven...

    journal_title:Inflammatory bowel diseases

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00054725-200108000-00009

    authors: Farup PG,Hinterleitner TA,Lukás M,Hébuterne X,Rachmilewitz D,Campieri M,Meier R,Keller R,Rathbone B,Oddsson E

    更新日期:2001-08-01 00:00:00

  • Micronutrient deficiencies in inflammatory bowel disease: from A to zinc.

    abstract::Inflammatory bowel disease (IBD) has classically been associated with malnutrition and weight loss, although this has become less common with advances in treatment and greater proportions of patients attaining clinical remission. However, micronutrient deficiencies are still relatively common, particularly in CD patie...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1002/ibd.22906

    authors: Hwang C,Ross V,Mahadevan U

    更新日期:2012-10-01 00:00:00

  • Characterizing Clinical Features and Creating a Gene Expression Profile Associated With Pain Burden in Children With Inflammatory Bowel Disease.

    abstract:BACKGROUND:There is often dissociation between inflammatory activity and abdominal pain in children with inflammatory bowel disease (IBD), suggesting other factors may play a role in the pain experience. METHODS:Patients (8 to 17 years) newly diagnosed with IBD were enrolled in the ALLAY Study: Assessing Risk Factors ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izz240

    authors: Grossi V,Hyams JS,Glidden NC,Knight BE,Young EE

    更新日期:2020-07-17 00:00:00

  • The position of the amino group on the benzene ring is critical for mesalamine's improvement of replication fidelity.

    abstract:BACKGROUND:Individuals with ulcerative colitis are at high risk of developing colitis-associated cancer. 5-Aminosalicylate (5-ASA) protects from cancer by its antiinflammatory activity as well as by altering cell growth, inducing apoptosis, and reducing replication errors. So far neither 5-ASA's structural specificity ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.21112

    authors: Campregher C,Luciani MG,Biesenbach P,Evstatiev R,Lyakhovich A,Gasche C

    更新日期:2010-04-01 00:00:00

  • Are endoscopic endpoints reliable in therapeutic trials of ulcerative colitis?

    abstract:BACKGROUND:The consistency of endoscopic and histologic findings in patients with ulcerative colitis (UC) has not been elucidated. Choice of assessment may affect study outcomes. METHODS:Post hoc analyses were performed using data from 2 randomized, controlled multicenter trials: (1) SAG-26, mesalazine granules for in...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/01.MIB.0000437044.43961.00

    authors: Wolff S,Terheggen G,Mueller R,Greinwald R,Franklin J,Kruis W

    更新日期:2013-11-01 00:00:00

  • Multiple Cytokine Profiling: A New Model to Predict Response to Tumor Necrosis Factor Antagonists in Ulcerative Colitis Patients.

    abstract:BACKGROUND AND AIMS:Ulcerative colitis (UC) is a form of inflammatory bowel disease, and antibodies against tumor necrosis factor (anti-TNF) are used for treatment. Many patients are refractory or lose response to anti-TNF, and predicting response would be an extremely valuable clinical tool. Unlike most biomarkers, cy...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izy358

    authors: Obraztsov IV,Shirokikh KE,Obraztsova OI,Shapina MV,Wang MH,Khalif IL

    更新日期:2019-02-21 00:00:00

  • Phase I trial of sargramostim in pediatric Crohn's disease.

    abstract:BACKGROUND:Improving granulocyte function may represent an effective therapy for Crohn's disease (CD). We performed a Phase I-2 trial of sargramostim (SRG) in children with CD. METHODS:This was multicenter, open-label study in 6-16-year-old patients with moderate to severely active CD. Patients received either 4 or 6 ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,多中心研究

    doi:10.1002/ibd.21204

    authors: Kelsen JR,Rosh J,Heyman M,Winter HS,Ferry G,Cohen S,Mamula P,Baldassano RN

    更新日期:2010-07-01 00:00:00

  • Phylogenetic analysis of inflammatory bowel disease associated Escherichia coli and the fimH virulence determinant.

    abstract:BACKGROUND:Evidence supports the role of adherent invasive Escherichia coli (AIEC) in the pathogenesis of inflammatory bowel disease (IBD). However, little is known about the phylogenetic structure and origin of this group of bacteria. Multi-locus sequence typing (MLST), and fimH sequence analysis were performed to elu...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.20966

    authors: Sepehri S,Kotlowski R,Bernstein CN,Krause DO

    更新日期:2009-11-01 00:00:00

  • Total CD3 T Cells Are Necessary and Sufficient to Induce Colitis in Immunodeficient Mice With Dendritic Cell-Specific Deletion of TGFbR2: A Novel IBD Model to Study CD4 and CD8 T-Cell Interaction.

    abstract:BACKGROUND:Inflammatory bowel disease (IBD) is a multifactorial disorder, with the innate and adaptive immune cells contributing to disease initiation and progression. However, the intricate cross-talk between immune cell lineages remains incompletely understood. The role of CD8+ T cells in IBD pathogenesis has been un...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izz191

    authors: Jamwal DR,Marati RV,Harrison CA,Midura-Kiela MT,Figliuolo Paz VR,Besselsen DG,Ghishan FK,Kiela PR

    更新日期:2020-01-06 00:00:00

  • Higher Adalimumab Levels Are Associated with Histologic and Endoscopic Remission in Patients with Crohn's Disease and Ulcerative Colitis.

    abstract:BACKGROUND:Optimal levels of adalimumab (ADA) have not been defined according to the ultimate goal of inflammatory bowel disease treatment--histologic and/or endoscopic healing. The aim of this study was to assess the relationship between random serum ADA levels and histologic and endoscopic healing in patients with in...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000689

    authors: Yarur AJ,Jain A,Hauenstein SI,Quintero MA,Barkin JS,Deshpande AR,Sussman DA,Singh S,Abreu MT

    更新日期:2016-02-01 00:00:00

  • The case for using 5-aminosalicyclates in Crohn's disease: pro.

    abstract::Mesalamine has a well-established role in the management of ulcerative colitis. However, its role in the management of Crohn's disease (CD) is less clear. Studies evaluating its therapeutic value in CD have produced both positive and negative results. Meta-analyses have not clarified the situation, possibly because th...

    journal_title:Inflammatory bowel diseases

    pub_type: 评论,社论

    doi:10.1097/01.mib.0000160743.24772.69

    authors: Hanauer SB

    更新日期:2005-06-01 00:00:00

  • Intestinal dendritic cells: their role in bacterial recognition, lymphocyte homing, and intestinal inflammation.

    abstract::Dendritic cells (DCs) play a key role in discriminating between commensal microorganisms and potentially harmful pathogens and in maintaining the balance between tolerance and active immunity. The regulatory role of DC is of particular importance in the gut where the immune system lies in intimate contact with the hig...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1002/ibd.21247

    authors: Ng SC,Kamm MA,Stagg AJ,Knight SC

    更新日期:2010-10-01 00:00:00

  • Apical Periodontitis in Patients With Inflammatory Bowel Disease: A Puppet Master?

    abstract::Focal infection theory posits that periodontal pathobionts play a causal role in initiating or exacerbating diseases. Periodontal disease is a common inflammatory, multifactorial disease of the periodontal tissues. The main factor for inflammation is mature dental plaque with the presence of pathogens in the microbial...

    journal_title:Inflammatory bowel diseases

    pub_type: 评论,社论

    doi:10.1093/ibd/izz129

    authors: Barta Z

    更新日期:2020-01-06 00:00:00

  • Roles of CD1d-restricted NKT cells in the intestine.

    abstract::Natural killer T (NKT) cells are a subset of lymphocytes that express cell surface molecules of both conventional T cells and natural killer cells and share the features of both innate and adaptive immune cells. NKT cells have been proposed to make both protective and pathogenic contributions to inflammatory bowel dis...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1002/ibd.20164

    authors: van Dieren JM,van der Woude CJ,Kuipers EJ,Escher JC,Samsom JN,Blumberg RS,Nieuwenhuis EE

    更新日期:2007-09-01 00:00:00

  • Intestinal antiinflammatory effects of thiazolidenedione peroxisome proliferator-activated receptor-gamma ligands on T helper type 1 chemokine regulation include nontranscriptional control mechanisms.

    abstract::Crohn's disease is associated with an excessive T helper (TH) type 1 inflammatory immune response. Reducing the influx of disease-associated CD4+ TH1 cells into the inflamed intestine is likely to be beneficial in preventing a disease flare-up and even possibly in reducing the effect of acute disease. Thiazolidenedion...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/01.mib.0000160770.94199.9b

    authors: Schaefer KL,Denevich S,Ma C,Cooley SR,Nakajima A,Wada K,Schlezinger J,Sherr D,Saubermann LJ

    更新日期:2005-03-01 00:00:00

  • Interleukin 23 in Crohn's disease.

    abstract::: Crohn's disease (CD) is a lifelong inflammatory condition with underlying environmental and genetic components. CD affects multiple parts of the gastrointestinal tract, and it has a growing incidence in Western societies. IL-23 receptor variants have been identified as susceptibility or resistance factors for CD in ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1097/01.MIB.0000442014.52661.20

    authors: Eken A,Singh AK,Oukka M

    更新日期:2014-03-01 00:00:00

  • Mechanisms that mediate the development of fibrosis in patients with Crohn's disease.

    abstract::Crohn's disease is complicated by the development of fibrosis and stricture in approximately 30% to 50% of patients over time. The pathogenesis of fibrostenotic disease is multifactorial involving the activation of mesenchymal cells by cytokines, growth factors, and other mediators released by immune cells, epithelial...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1097/MIB.0000000000000043

    authors: Li C,Kuemmerle JF

    更新日期:2014-07-01 00:00:00

  • Validation of a Simple 0 to 10 Numerical Score (IBD-10) of Patient-reported Inflammatory Bowel Disease Activity for Routine Clinical Use.

    abstract:BACKGROUND:Various physician- and patient-reported instruments exist for quantification of disease activity in inflammatory bowel diseases (IBD) but none are widely used in routine clinical practice. A simple patient-reported outcome measure might help inform clinical decision making. We evaluated a patient-reported 0 ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000803

    authors: Subramanian S,Asher R,Weston W,Rimmer M,McConville A,Malin A,Jackson R,Collins P,Probert C,Dibb M,Rhodes JM

    更新日期:2016-08-01 00:00:00

  • Stopping Biologics in IBD-What Is the Evidence?

    abstract::Biologic treatments have revolutionized the way we treat inflammatory bowel disease patients (IBD). Anti-tumor necrosis factor (anti-TNF) antibodies are superior to conventional therapies to achieve sustained remission without steroids and mucosal healing. The objective of IBD treatment has evolved from symptom allevi...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1093/ibd/izx098

    authors: Louis E

    更新日期:2018-03-19 00:00:00

  • Immune System Activation in C3H/HeJBir Mice Exhibiting Spontaneous Perianal Ulceration.

    abstract::: We report our initial characterization of the immune system in C3H/HeJBir mice that spontaneously develop perianal ulceration. Analysis of lymphokine production by mucosal and systemic lymphoid cells obtained from these mice revealed higher levels of interleukin (IL)4 in supernatants of in vitro stimulated Peyer's p...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:

    authors: Tonkonogy SL,Sartor BR

    更新日期:1997-04-01 00:00:00

  • Distinct Anti-IFI16 and Anti-GP2 Antibodies in Inflammatory Bowel Disease and Their Variation with Infliximab Therapy.

    abstract:BACKGROUND:Inflammatory bowel disease (IBD) is characterized by a chronic inflammation of the gut, partly driven by defects in the expression and function of pattern recognition receptors, including the IFI16 protein. Because this protein is a target for autoantibodies and its aberrant expression was reported in coloni...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000926

    authors: Caneparo V,Pastorelli L,Pisani LF,Bruni B,Prodam F,Boldorini R,Roggenbuck D,Vecchi M,Landolfo S,Gariglio M,De Andrea M

    更新日期:2016-12-01 00:00:00

  • Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn's disease.

    abstract:BACKGROUND:Crohn's disease (CD)-associated dysbiosis could predispose patients to relapse. Gut microbiota composition of patients from the prospective cohort study designed to identify predictive factors of clinical relapse after infliximab discontinuation (STORI Study) was investigated to determine the impact of dysbi...

    journal_title:Inflammatory bowel diseases

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1097/MIB.0000000000000036

    authors: Rajca S,Grondin V,Louis E,Vernier-Massouille G,Grimaud JC,Bouhnik Y,Laharie D,Dupas JL,Pillant H,Picon L,Veyrac M,Flamant M,Savoye G,Jian R,Devos M,Paintaud G,Piver E,Allez M,Mary JY,Sokol H,Colombel JF,Seksik P

    更新日期:2014-06-01 00:00:00

  • Short pediatric Crohn's disease activity index for quality improvement and observational research.

    abstract:BACKGROUND:Practical and objective instruments to assess pediatric Crohn's disease (CD) activity are required for observational research and quality improvement. The objectives were: 1) to determine the feasibility of completing the Pediatric Crohn's Disease Activity Index (PCDAI) and the Abbreviated PCDAI (APCDAI); an...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.21452

    authors: Kappelman MD,Crandall WV,Colletti RB,Goudie A,Leibowitz IH,Duffy L,Milov DE,Kim SC,Schoen BT,Patel AS,Grunow J,Larry E,Fairbrother G,Margolis P

    更新日期:2011-01-01 00:00:00

  • A Critical Role for Monocytes/Macrophages During Intestinal Inflammation-associated Lymphangiogenesis.

    abstract:BACKGROUND:Inflammation-associated lymphangiogenesis (IAL) is frequently observed in inflammatory bowel diseases. IAL is believed to limit inflammation by enhancing fluid and immune cell clearance. Although monocytes/macrophages (MΦ) are known to contribute to intestinal pathology in inflammatory bowel disease, their r...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000731

    authors: Becker F,Kurmaeva E,Gavins FN,Stevenson EV,Navratil AR,Jin L,Tsunoda I,Orr AW,Alexander JS,Ostanin DV

    更新日期:2016-06-01 00:00:00

  • Phenotype classification in IBD: Is there an impact on therapy?

    abstract::This review summarizes the current phenotypic classifications of inflammatory bowel disease (IBD) and outlines their implications for diagnosis, therapy, prognosis, clinical trial design, and genotype-phenotype correlations. ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.20232

    authors: Walfish A,Sachar D

    更新日期:2007-12-01 00:00:00

  • Adverse Pregnancy Outcomes Among Women with Inflammatory Bowel Disease: A Population-Based Study from England.

    abstract:BACKGROUND:There is limited contemporary population-based evidence on adverse birth outcomes and pregnancy-related complications for women with inflammatory bowel disease (IBD). This study provides such estimates of these risks and assesses variation by IBD type and surgical interventions. METHODS:We calculated the pr...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000802

    authors: Abdul Sultan A,West J,Ban L,Humes D,Tata LJ,Fleming KM,Nelson-Piercy C,Card T

    更新日期:2016-07-01 00:00:00

  • Tyro3, Axl, and Mertk receptor signaling in inflammatory bowel disease and colitis-associated cancer.

    abstract::Three receptor tyrosine kinases, Tyro3, Axl, and Mertk (TAM) and their ligands Gas6 and Protein S, have emerged as potent negative regulators of innate immune responses. A number of studies using genetic ablation of TAM loci in mice have elucidated the mechanism of TAM engagement and function during the immune respons...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1097/MIB.0000000000000050

    authors: Rothlin CV,Leighton JA,Ghosh S

    更新日期:2014-08-01 00:00:00

  • Development and Validation of a Confocal Laser Endomicroscopy-Based Score for In Vivo Assessment of Mucosal Healing in Ulcerative Colitis Patients.

    abstract:Background:Endoscopic monitoring is fundamental for evaluating the therapeutic response in IBD, but a validated endomicroscopic mucosal healing (MH) score is not available to date. However, confocal laser endomicroscopy (CLE) might define MH more precisely than conventional endoscopy. The major aim was to establish and...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izx012

    authors: Hundorfean G,Chiriac MT,Mihai S,Hartmann A,Mudter J,Neurath MF

    更新日期:2017-12-19 00:00:00

  • Successful treatment of an acute flare of steroid-resistant Crohn's colitis during pregnancy with unfractionated heparin.

    abstract::Recent reports suggest that unfractionated heparin may be a useful adjunct in the treatment of inflammatory bowel disease (IBD). We report the successful use of subcutaneous unfractionated heparin to treat a moderate-to-severe flare of Crohn's disease during pregnancy, which was refractory to standard therapy. The pat...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/00054725-200205000-00006

    authors: Prajapati DN,Newcomer JR,Emmons J,Abu-Hajir M,Binion DG

    更新日期:2002-05-01 00:00:00